A 58-year-old woman with a 10-year history of rheumatoid arthritis (RA) on methotrexate and prednisolone presents with progressive dyspnea and dry cough for 3 months. High-resolution CT chest shows bilateral lower lobe predominant reticular opacities with traction bronchiectasis. Pulmonary function tests reveal FVC 65% predicted and DLCO 52% predicted. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a serious extra-articular manifestation of chronic RA. The HRCT pattern (lower lobe reticular opacities with traction bronchiectasis) is consistent with usual interstitial pneumonia (UIP), which carries a poor prognosis. ## Pathophysiology of RA-ILD **Key Point:** RA-ILD is driven by chronic immune-mediated inflammation and abnormal fibroblast activation. The presence of a UIP pattern on HRCT indicates progressive pulmonary fibrosis and warrants disease-modifying antifibrotic therapy. **High-Yield:** The combination of: - HRCT findings suggestive of UIP (reticular opacities, traction bronchiectasis, lower lobe predominance) - Reduced FVC and DLCO - Progressive dyspnea ...indicates advanced RA-ILD requiring antifibrotic agents (pirfenidone or nintedanib) in addition to RA-specific therapy. ## Management Pathway for RA-ILD ```mermaid flowchart TD A[RA-ILD diagnosed on HRCT]:::outcome --> B{UIP pattern present?}:::decision B -->|Yes| C[Confirm UIP pattern]:::action B -->|No| D[Observe, optimize RA therapy]:::action C --> E[Initiate antifibrotic agent]:::action E --> F[Pirfenidone or Nintedanib]:::action F --> G[Continue DMARD + steroids]:::action G --> H[Monitor PFTs, HRCT at 6-12 months]:::action D --> I[Repeat imaging in 3-6 months]:::action ``` ## Why Antifibrotic Therapy is Essential **Clinical Pearl:** Pirfenidone and nintedanib have demonstrated efficacy in slowing the decline of FVC in idiopathic pulmonary fibrosis (IPF) and are increasingly used in RA-ILD with UIP pattern. These agents target the fibrotic cascade and reduce progression. **Mnemonic:** **UIP + RA-ILD = AFT** — **U**sual **I**nterstitial **P**neumonia + **RA**-associated **ILD** = **A**nti**F**ibrotic **T**herapy. ## Why Other Options Are Incorrect ### Option 0: Observation Alone **Warning:** Observation without antifibrotic therapy in a patient with UIP pattern and declining PFTs is inappropriate. This approach leads to progressive fibrosis, respiratory failure, and death. The DLCO of 52% predicted indicates significant gas exchange impairment. ### Option 2: Switching to TNF Inhibitor **Warning:** While TNF inhibitors are effective for RA control, they do NOT address the underlying pulmonary fibrosis. Moreover, TNF inhibitors can paradoxically worsen or unmask ILD in some RA patients. They are not antifibrotic agents. ### Option 3: Bronchoscopy with BAL **Warning:** BAL is not indicated in a patient with a clear UIP pattern on HRCT and clinical/functional evidence of ILD. BAL may be considered in smear-negative, culture-negative cases to exclude infection, but this patient's presentation is classic for fibrotic ILD, not infection.